INFECTIOUS DISEASES
Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level LISELOTTE C. VAN There is evidence that HIV-positive injecting drug users benefit less than other risk groups from highly active antiretroviral therapy that has been available since 1996. In this multicentre European study the impact of the availability of highly active antiretroviral therapy on the progression rates to AIDS and death among injecting drug users with a documented date of HIV seroconversion is studied. After highly active antiretroviral therapy became available the risk of AIDS and death for injecting drug users decreased by 28% and 36%, which is less than has been reported for other risk groups.
Keywords: Europe, highly active antiretroviral therapy, HIV disease progression, IV drug users, survival analysis -Lt is not yet clear whether HIV-positive injecting drug users (IDU) benefit as much as other risk groups from the general availability since 1996 of HAART {highly active antiretroviral therapy). Studies on the population level that include, among others, the IDU risk group, do show a reduced risk of AIDS and death in 1997 and 1998 M and these improvements have been shown to be associated with therapy usage. However, most of these studies concern seroprevalent cohorts in which adjusting fully for duration ot HIV infection is not possible, which leads to survival estimates in the HAART era that are too optimistic. 6 Only two studies of seroconverters (thus with 
DISCUSSION
Until 1993 the incubation period from HIV seroconversion to AIDS in IDU was estimated to be 10. 2-11.6 years.
We assume the increased risk of AIDS in the 1993 to 1996 time period to be attributable to the extension of the European AIDS case definition as two of three added diseases are mainly afflicting IDU and no changes in progression have been reported for earlier calendar periods despite earlier definition changes and the introduction of mono and bitherapy.
However, when ignoring this increased risk of AIDS that is probably due to the 1993 AIDS definition, our estimated risk reduction of AIDS among IDU in the time of highly active antiretroviral therapy was altered only minimally. " 22-30 1QR 1986 -1992 :IQR: In i iur study, the first effect of the availability of HAART among 1DU with documented HIV seroconversion is an approximate 28% decrease in risk of developing AIDS and 36% decrease in mortality. The survival benefit in our study is less than that reported in the CASCADE study in the same study period, where the overall decrease in mortality following HAART introduction was 64%, with no difference by risk group. 7 The survival benefit in our study is also less than the 50% decrease in mortality among Italian seroconverters. The latter study does mention that the reduction was less pronounced among IDU, but not to which extent. 5 Not only less HAART uptake, but also pre-AIDS deaths of natural causes (liver failure, bacterial infections), which are more common among IDU than other risk groups, may play a role in the limited effect of HAART on mortality. 12 Future analyses including more follow-up time and details on individual treatment compliance will let us know whether IDU do indeed benefit less from the availability of HAART than other risk groups. 
